Masimo (NASDAQ:MASI) updated its FY 2019
Pre-Market earnings guidance on Tuesday. The company provided EPS guidance of 3.18 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.17. The company issued revenue guidance of $934-937 million, compared to the consensus revenue estimate of $947.01 million.Masimo also updated its FY 2020
Pre-Market guidance to 3.56-3.56 EPS.
Several research firms have weighed in on MASI. ValuEngine lowered shares of Masimo from a buy rating to a hold rating in a research note on Wednesday, October 2nd. Piper Jaffray Companies reiterated an overweight rating and set a $175.00 target price (up previously from $161.00) on shares of Masimo in a research note on Tuesday, December 17th. Finally, BidaskClub upgraded shares of Masimo from a hold rating to a buy rating in a research note on Monday, December 16th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $161.75.
Shares of Masimo stock traded down $3.04 during trading on Tuesday, hitting $161.96. 2,131 shares of the stock were exchanged, compared to its average volume of 302,750. The stock’s fifty day moving average is $157.78 and its 200 day moving average is $151.93. The stock has a market cap of $8.68 billion, a PE ratio of 53.28, a P/E/G ratio of 2.02 and a beta of 1.13. Masimo has a 12 month low of $110.98 and a 12 month high of $165.48.
Masimo (NASDAQ:MASI) last released its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $0.76 EPS for the quarter, topping the consensus estimate of $0.73 by $0.03. The business had revenue of $229.01 million during the quarter, compared to analyst estimates of $221.92 million. Masimo had a net margin of 20.83% and a return on equity of 17.32%. The company’s quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.71 earnings per share. Sell-side analysts expect that Masimo will post 3.17 EPS for the current fiscal year.
In related news, EVP Thomas Samuel Mcclenahan sold 500 shares of the company’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $159.29, for a total value of $79,645.00. Following the completion of the sale, the executive vice president now owns 5,607 shares of the company’s stock, valued at $893,139.03. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Sanford Fitch sold 6,500 shares of the company’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $147.08, for a total transaction of $956,020.00. Following the completion of the sale, the director now directly owns 50,745 shares of the company’s stock, valued at approximately $7,463,574.60. The disclosure for this sale can be found here. Insiders have sold 56,000 shares of company stock valued at $8,683,715 in the last 90 days. Insiders own 11.50% of the company’s stock.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Recommended Story: How are dividend achievers different from dividend aristocrats?
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.